Biomea Fusion
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 103
- Market Cap
- -
- Website
- http://biomeafusion.com
- Introduction
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Biomea Fusion Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT06152042
- Locations
- 🇺🇸
Sutter Valley Medical Foundation Pediatric Endocrinology, Sacramento, California, United States
🇺🇸Diablo Clinical Research,Inc, Walnut Creek, California, United States
🇺🇸Southwest General Healthcare Center, Fort Myers, Florida, United States
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Biomea Fusion Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05918692
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCLA Department of Medicine, Los Angeles, California, United States
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Biomea Fusion Inc.
- Target Recruit Count
- 414
- Registration Number
- NCT05731544
- Locations
- 🇺🇸
David Kavtaradze MD, Inc, Cordele, Georgia, United States
🇺🇸Hope Clinical Research, Canoga Park, California, United States
🇺🇸Ark Clinical Research, LLC, Fountain Valley, California, United States
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
- Conditions
- Non Small Cell Lung CancerPancreatic CancerColorectal CancerNSCLCPDACCRCRelapsed CancerRefractory CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Biomea Fusion Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05631574
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center of Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
- Conditions
- LymphomaMyeloma, Plasma-CellSmall Lymphocytic LymphomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelomatosisPlasma Cell MyelomaChronic Lymphocytic LeukemiaAcute Mixed-Phenotype LeukemiaCancer
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Biomea Fusion Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05153330
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸University of Southern California Norris Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine, Los Angeles, California, United States